Testing positive for BRCA2 means you carry an inherited change (mutation) in one copy of the BRCA2 gene that prevents it from working properly. This doesn’t mean you have cancer or will definitely develop it, but it does significantly raise your lifetime risk for several types of cancer compared to the general population. Each of your children has a 50% chance of inheriting the same mutation.
What the BRCA2 Gene Normally Does
The BRCA2 protein works inside the nucleus of your cells to repair breaks in DNA. These breaks happen constantly from normal processes like cell division, as well as from environmental factors like radiation and chemical exposures. When BRCA2 is functioning correctly, it teams up with other proteins to fix those breaks before they cause problems.
When one copy of the gene carries a harmful mutation, your cells lose some of that repair ability. Damaged DNA accumulates more easily, and cells are more likely to grow out of control. That’s the core reason a BRCA2 mutation raises cancer risk: your body’s built-in system for catching and fixing genetic errors is compromised.
Cancer Risks for Women
The cancers most strongly linked to BRCA2 are breast and ovarian cancer. Women in the general population have roughly a 13% lifetime risk of breast cancer. For women with a BRCA2 mutation, that number climbs substantially, with estimates commonly cited in the range of 45% to 72% by age 70 to 80, depending on family history and other factors.
Ovarian cancer risk also rises meaningfully. In the general population, a woman’s lifetime risk is about 1.2%. With a BRCA2 mutation, estimates range from roughly 11% to 17%. BRCA2 also carries an elevated risk of pancreatic cancer, with an absolute risk of approximately 2.5% by age 80, about three times higher than average. Earlier research suggested a link to melanoma, but more recent large-scale studies have not confirmed that association.
Cancer Risks for Men
BRCA2 is not just a women’s health issue. Men with a BRCA2 mutation face a notably higher risk of prostate cancer: between 19% and 61% by age 80, according to the National Cancer Institute. BRCA2-related prostate cancers also tend to be more aggressive and diagnosed at a younger age than typical prostate cancers.
Male breast cancer, while still uncommon overall, is far more likely in BRCA2 carriers. Between 1.8% and 7.1% of men with a BRCA2 mutation will develop breast cancer by age 70. In the general male population, that risk is well under 0.1%. Men with BRCA2 mutations also share the elevated pancreatic cancer risk.
Recommended Screening Schedule
Because early detection dramatically improves outcomes, screening for BRCA2 carriers starts earlier and happens more frequently than standard guidelines. The National Comprehensive Cancer Network (NCCN) recommends the following for women with a BRCA2 mutation:
- Age 18: Begin breast self-awareness.
- Age 25: Clinical breast exams every 6 to 12 months.
- Ages 25 to 29: Annual breast MRI. If a family member was diagnosed with breast cancer before age 30, the plan may be individualized earlier.
- Ages 30 to 75: Annual mammogram and annual breast MRI.
- After 75: Screening is individualized based on your overall health.
Men with BRCA2 mutations are typically advised to start prostate cancer screening earlier than the general population (often around age 40) and to discuss breast self-exams with their doctor. Pancreatic cancer screening may also be recommended if there is a family history of the disease.
Options for Reducing Risk
Knowing your BRCA2 status gives you the chance to act before cancer develops. The two major preventive strategies are enhanced surveillance (the screening schedule above) and risk-reducing surgery.
Preventive removal of the ovaries and fallopian tubes (called a risk-reducing salpingo-oophorectomy) has been studied extensively. In BRCA mutation carriers, this procedure reduces breast cancer risk by roughly 50% to 60% and dramatically lowers ovarian cancer risk. Many carriers choose this surgery after completing childbearing, typically in their late 30s or 40s. It also triggers early menopause, so the timing involves balancing cancer risk against the effects of hormone loss.
Preventive mastectomy is another option that reduces breast cancer risk by approximately 90% or more. Some carriers choose this route, while others prefer close monitoring with imaging. Neither choice is universally “right,” and the decision depends on your personal risk numbers, family history, and how you weigh the tradeoffs.
Treatment Differences if Cancer Develops
If you do develop cancer as a BRCA2 carrier, your mutation status actually opens the door to targeted therapies. A class of drugs called PARP inhibitors works by exploiting the same DNA repair weakness that made the cancer possible in the first place. Your cancer cells already can’t fix DNA properly because of the BRCA2 mutation. PARP inhibitors block a second, backup repair pathway, which forces cancer cells to accumulate so much damage that they die.
Several PARP inhibitors are FDA-approved for BRCA-related breast, ovarian, pancreatic, and prostate cancers. These drugs are taken as pills and are often used after initial treatment to help prevent recurrence. They represent a meaningful advantage that BRCA2 carriers have over people with the same cancers caused by non-hereditary factors.
Passing It to Your Children
BRCA2 mutations follow an autosomal dominant inheritance pattern. You carry one working copy and one mutated copy of the gene, and each child you have gets one copy or the other. That means every pregnancy carries a 50% chance of passing along the mutation, regardless of the child’s sex. Sons and daughters are equally likely to inherit it.
Many carriers wrestle with when and how to discuss this with their children. Genetic testing is generally offered once children reach adulthood (18 or older), since management recommendations begin around that age. Some families choose to pursue genetic counseling together so everyone understands what the results mean and what steps are available.